Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies.

Humans Female Breast Neoplasms / drug therapy BRCA1 Protein / genetics BRCA2 Protein / genetics Germ-Line Mutation Phthalazines / therapeutic use
OlympiA adjuvant early breast cancer germline BRCA olaparib

Journal

The oncologist
ISSN: 1549-490X
Titre abrégé: Oncologist
Pays: England
ID NLM: 9607837

Informations de publication

Date de publication:
05 07 2023
Historique:
received: 23 01 2023
accepted: 06 04 2023
medline: 7 7 2023
pubmed: 21 5 2023
entrez: 20 5 2023
Statut: ppublish

Résumé

In the OlympiA study, 1 year of adjuvant olaparib significantly extended invasive disease-free survival and overall survival. The benefit was consistent across subgroups, and this regimen is now recommended after chemotherapy for germline BRCA1/2 mutation (gBRCA1/2m) carriers with high-risk, HER2-negative early breast cancer. However, the integration of olaparib in the landscape of agents currently available in the post(neo)adjuvant setting-ie, pembrolizumab, abemaciclib, and capecitabine-is challenging, as there are no data suggesting how to select, sequence, and/or combine these therapeutic approaches. Furthermore, it is unclear how to best identify additional patients who could benefit from adjuvant olaparib beyond the original OlympiA criteria. Since it is unlikely that new clinical trials will answer these questions, recommendations for clinical practice can be made through indirect evidence. In this article, we review available data that could help guide treatment decisions for gBRCA1/2m carriers with high-risk, early-stage breast cancer.

Identifiants

DOI: 10.1093/oncolo/oyad123 PMID: 37210568 PMC: PMC10322138
pubmed: 37210568
pii: 7175048
doi: 10.1093/oncolo/oyad123
pmc: PMC10322138
doi:

Substances chimiques

olympia 71714-89-1
BRCA1 protein, human 0
BRCA1 Protein 0
olaparib WOH1JD9AR8
BRCA2 protein, human 0
BRCA2 Protein 0
Phthalazines 0

Types de publication

Review Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

565-574

Informations de copyright

© The Author(s) 2023. Published by Oxford University Press.

Références

Cancer. 2016 Apr 15;122(8):1178-84
pubmed: 26859126
Hum Reprod. 2020 Aug 1;35(8):1864-1874
pubmed: 32604417
N Engl J Med. 2018 Jul 12;379(2):111-121
pubmed: 29860917
Ann Oncol. 2022 Dec;33(12):1250-1268
pubmed: 36228963
ESMO Open. 2021 Feb;6(1):100033
pubmed: 33444891
Lancet Haematol. 2021 Feb;8(2):e122-e134
pubmed: 33347814
J Clin Oncol. 2022 Oct 10;40(29):3361-3364
pubmed: 35675571
NPJ Breast Cancer. 2021 Nov 11;7(1):142
pubmed: 34764307
Br J Cancer. 2021 Apr;124(9):1524-1532
pubmed: 33597716
JCO Precis Oncol. 2018 Nov;2:1-5
pubmed: 35135128
Histol Histopathol. 2021 Dec;36(12):1235-1245
pubmed: 34585734
J Natl Cancer Inst. 2021 Aug 2;113(8):1005-1016
pubmed: 33523233
Breast Cancer Res Treat. 2016 Jun;157(3):511-6
pubmed: 27225387
J Clin Oncol. 2011 May 20;29(15):1956-62
pubmed: 21482989
JAMA Netw Open. 2022 Sep 1;5(9):e2232787
pubmed: 36136330
J Clin Oncol. 2014 Jul 10;32(20):2142-50
pubmed: 24888816
J Clin Oncol. 2020 Apr 20;38(12):1346-1366
pubmed: 31928404
JAMA Oncol. 2016 Jul 1;2(7):929-36
pubmed: 26986538
J Clin Oncol. 2020 Jan 20;38(3):203-213
pubmed: 31804894
Breast Cancer Res Treat. 2014 Jul;146(1):175-82
pubmed: 24839033
J Clin Oncol. 2020 Feb 10;38(5):388-394
pubmed: 31461380
J Clin Oncol. 2008 Jan 10;26(2):246-52
pubmed: 18056680
Oncogene. 2006 Sep 25;25(43):5846-53
pubmed: 16998499
N Engl J Med. 2021 Feb 4;384(5):428-439
pubmed: 33471991
Breast Cancer Res. 2010;12(1):R12
pubmed: 20149218
N Engl J Med. 2022 Feb 10;386(6):556-567
pubmed: 35139274
Ann Oncol. 2021 Nov;32(11):1410-1424
pubmed: 34419555
Nature. 2012 Oct 4;490(7418):61-70
pubmed: 23000897
J Clin Oncol. 2020 May 1;38(13):1409-1418
pubmed: 32125938
N Engl J Med. 2021 Feb 4;384(5):440-451
pubmed: 33471974
Ann Oncol. 2020 Nov;31(11):1526-1535
pubmed: 32828825
JCO Oncol Pract. 2022 Jun;18(6):427-429
pubmed: 34995080
J Clin Oncol. 2020 Dec 20;38(36):4274-4282
pubmed: 33119476
Cancer. 2015 Oct 1;121(19):3422-7
pubmed: 26280679
Ann Oncol. 2021 Dec;32(12):1571-1581
pubmed: 34656740
J Clin Oncol. 2021 Aug 10;39(23):2539-2551
pubmed: 34092112
Lancet Oncol. 2020 Sep;21(9):1155-1164
pubmed: 32771088
Lancet Oncol. 2022 Sep;23(9):1124-1126
pubmed: 36055301
J Clin Oncol. 2022 May 20;40(15):1696-1698
pubmed: 35417251
Nat Commun. 2022 Nov 7;13(1):6728
pubmed: 36344544
J Natl Cancer Inst. 2020 Jul 1;112(7):728-736
pubmed: 31742342
Front Oncol. 2021 Feb 19;11:636266
pubmed: 33680973
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Cancer. 2021 Mar 15;127(6):828-833
pubmed: 33146899
NPJ Breast Cancer. 2021 Feb 12;7(1):16
pubmed: 33579978
JAMA Oncol. 2019 Aug 01;5(8):1132-1140
pubmed: 31194225
JNCI Cancer Spectr. 2020 Sep 18;5(1):
pubmed: 33426465
Ann Oncol. 2019 Apr 1;30(4):558-566
pubmed: 30689707
Nat Cancer. 2022 Oct;3(10):1181-1191
pubmed: 36253484
Lancet Oncol. 2023 Jan;24(1):77-90
pubmed: 36493792
Ann Oncol. 2019 Aug 1;30(8):1194-1220
pubmed: 31161190
N Engl J Med. 2017 Jun 1;376(22):2147-2159
pubmed: 28564564
J Clin Oncol. 2023 Jan 20;41(3):609-617
pubmed: 36082969
N Engl J Med. 2020 Feb 27;382(9):810-821
pubmed: 32101663
Ann Surg Oncol. 2019 Oct;26(10):3025-3031
pubmed: 31342359
Lancet Oncol. 2018 Feb;19(2):169-180
pubmed: 29337092
J Clin Oncol. 2008 Sep 10;26(26):4282-8
pubmed: 18779615
N Engl J Med. 2021 Jun 24;384(25):2394-2405
pubmed: 34081848
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
Cancer. 2020 Jan 15;126(2):271-280
pubmed: 31581314

Auteurs

Stefania Morganti (S)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Boston, MA, USA.
Division of New Drugs and Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Brittany L Bychkovsky (BL)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Division of Genetics and Prevention Program, Dana-Farber Cancer Institute, Boston, MA, USA.

Philip D Poorvu (PD)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Ana C Garrido-Castro (AC)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Broad Institute of MIT and Harvard, Boston, MA, USA.

Anna Weiss (A)

Department of Surgery, Division of Surgical Oncology, University of Rochester, Rochester, NY, USA.

Caroline C Block (CC)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Ann H Partridge (AH)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Giuseppe Curigliano (G)

Division of New Drugs and Early Drug Development, European Institute of Oncology, IRCCS, Milan, Italy.
Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

Nadine M Tung (NM)

Harvard Medical School, Boston, MA, USA.
Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Boston, MA, USA.

Nancy U Lin (NU)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Judy E Garber (JE)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
Division of Genetics and Prevention Program, Dana-Farber Cancer Institute, Boston, MA, USA.

Sara M Tolaney (SM)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.

Filipa Lynce (F)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harvard Medical School, Boston, MA, USA.
ORCID: 0000-0001-6615-7076

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Adjuvant Olaparib for Germline BRCA Carriers...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Adjuvant Olaparib for Germline BRCA Carriers...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Protéine BRCA1 › Adjuvant Olaparib for Germline BRCA Carriers...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › Protéine BRCA2 › Adjuvant Olaparib for Germline BRCA Carriers...
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Mutation germinale › Adjuvant Olaparib for Germline BRCA Carriers...
questionsmedicales.fr › Composés hétérocycliques › Composés hétéromonocycliques › Pyridazines › Phtalazines › Adjuvant Olaparib for Germline BRCA Carriers...